Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.63
-0.04-2.40%
Pre-Market: 4:03 PM EDT
Comments
Loading...
Aclaris Therapeutics Analyst Ratings and Price Targets | NASDAQ:ACRS | Benzinga
Aclaris Therapeutics Inc has a consensus price target of $12.67 based on the ratings of 12 analysts. The high is $22 issued by Evercore ISI Group on October 3, 2023. The low is $1 issued by Stifel on December 18, 2023. The 3 most-recent analyst ratings were released by Scotiabank, HC Wainwright & Co., and Leerink Partners on March 7, 2025, December 23, 2024, and November 19, 2024, respectively. With an average price target of $14 between Scotiabank, HC Wainwright & Co., and Leerink Partners, there's an implied 758.90% upside for Aclaris Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Scotiabank
HC Wainwright & Co.
Leerink Partners
Jefferies
BTIG
1calculated from analyst ratings
Analyst Ratings for Aclaris Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/18/2025 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal39% | — | Reiterates | Overweight → Overweight | Get Alert |
| 03/07/2025 | Buy Now | 820.25% | Scotiabank | Louise Chen58% | → $15 | Initiates | → Sector Outperform | Get Alert |
| 12/23/2024 | Buy Now | 1126.99% | HC Wainwright & Co. | Raghuram Selvaraju43% | $20 → $20 | Upgrade | Neutral → Buy | Get Alert |
| 11/19/2024 | Buy Now | 329.45% | Leerink Partners | Thomas Smith33% | $2 → $7 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/19/2024 | Buy Now | 329.45% | Jefferies | Roger Song33% | $2 → $7 | Upgrade | Hold → Buy | Get Alert |
| 11/19/2024 | Buy Now | 390.8% | BTIG | Julian Harrison41% | → $8 | Upgrade | Neutral → Buy | Get Alert |
| 11/18/2024 | Buy Now | 697.55% | Piper Sandler | Christopher Raymond57% | $3 → $13 | Upgrade | Neutral → Overweight | Get Alert |
| 09/17/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju43% | — | Reiterates | → Neutral | Get Alert |
| 08/19/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju43% | — | Reiterates | → Neutral | Get Alert |
| 07/22/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju43% | — | Reiterates | → Neutral | Get Alert |
| 01/22/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju43% | — | Downgrade | Buy → Neutral | Get Alert |
| 01/11/2024 | Buy Now | — | BTIG | Julian Harrison41% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/29/2023 | Buy Now | 452.15% | HC Wainwright & Co. | Raghuram Selvaraju43% | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2023 | Buy Now | -38.65% | Stifel | Alex Thompson45% | $2 → $1 | Maintains | Hold | Get Alert |
| 11/14/2023 | Buy Now | 452.15% | HC Wainwright & Co. | Raghuram Selvaraju43% | $43 → $9 | Maintains | Buy | Get Alert |
| 11/14/2023 | Buy Now | — | Cantor Fitzgerald | Louise Chen58% | — | Downgrade | Overweight → Neutral | Get Alert |
| 11/13/2023 | Buy Now | 22.7% | Stifel | Alex Thompson45% | $20 → $2 | Downgrade | Buy → Hold | Get Alert |
| 11/13/2023 | Buy Now | — | William Blair | Tim Lugo34% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 10/09/2023 | Buy Now | 2231.29% | Cantor Fitzgerald | Louise Chen58% | → $38 | Reiterates | Overweight → Overweight | Get Alert |
| 10/04/2023 | Buy Now | 2538.04% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $43 | Reiterates | Buy → Buy | Get Alert |
| 10/03/2023 | Buy Now | 1249.69% | Evercore ISI Group | Gavin Clark-Gartner41% | → $22 | Initiates | → Outperform | Get Alert |
| 09/19/2023 | Buy Now | 2231.29% | Cantor Fitzgerald | Louise Chen58% | → $38 | Reiterates | Overweight → Overweight | Get Alert |
| 09/19/2023 | Buy Now | 2538.04% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $43 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | Buy Now | 1126.99% | Stifel | Alex Thompson45% | $16 → $20 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | 2538.04% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $43 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2023 | Buy Now | 2538.04% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $43 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2023 | Buy Now | 1188.34% | Goldman Sachs | Corinne Jenkins46% | $25 → $21 | Maintains | Buy | Get Alert |
| 03/07/2023 | Buy Now | 1679.14% | BTIG | Julian Harrison41% | $32 → $29 | Maintains | Buy | Get Alert |
| 03/07/2023 | Buy Now | 2538.04% | HC Wainwright & Co. | Raghuram Selvaraju43% | $50 → $43 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 2967.48% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $50 | Reiterates | → Buy | Get Alert |
| 02/07/2023 | Buy Now | 2231.29% | Cantor Fitzgerald | Louise Chen58% | → $38 | Reiterates | → Overweight | Get Alert |
| 12/14/2022 | Buy Now | 1679.14% | Stifel | Alex Thompson45% | → $29 | Initiates | → Buy | Get Alert |
| 12/01/2022 | Buy Now | 1433.74% | Goldman Sachs | Corinne Jenkins46% | → $25 | Initiates | → Buy | Get Alert |
| 10/06/2022 | Buy Now | 1863.19% | BTIG | Julian Harrison41% | → $32 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Aclaris Therapeutics (ACRS) stock?
The latest price target for Aclaris Therapeutics (NASDAQ:ACRS) was reported by Cantor Fitzgerald on March 18, 2025. The analyst firm set a price target for $0.00 expecting ACRS to fall to within 12 months (a possible -100.00% downside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aclaris Therapeutics (ACRS)?
The latest analyst rating for Aclaris Therapeutics (NASDAQ:ACRS) was provided by Cantor Fitzgerald, and Aclaris Therapeutics reiterated their overweight rating.
When was the last upgrade for Aclaris Therapeutics (ACRS)?
The last upgrade for Aclaris Therapeutics Inc happened on December 23, 2024 when HC Wainwright & Co. raised their price target to $20. HC Wainwright & Co. previously had a neutral for Aclaris Therapeutics Inc.
When was the last downgrade for Aclaris Therapeutics (ACRS)?
The last downgrade for Aclaris Therapeutics Inc happened on January 22, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Aclaris Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Aclaris Therapeutics (ACRS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aclaris Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aclaris Therapeutics was filed on March 18, 2025 so you should expect the next rating to be made available sometime around March 18, 2026.
Is the Analyst Rating Aclaris Therapeutics (ACRS) correct?
While ratings are subjective and will change, the latest Aclaris Therapeutics (ACRS) rating was a reiterated with a price target of $0.00 to $0.00. The current price Aclaris Therapeutics (ACRS) is trading at is $1.63, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.